Fred Alger Management LLC Acquires 200,259 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fred Alger Management LLC raised its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 82.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 443,642 shares of the biopharmaceutical company’s stock after purchasing an additional 200,259 shares during the period. Fred Alger Management LLC’s holdings in Celldex Therapeutics were worth $12,471,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Silverarc Capital Management LLC increased its stake in shares of Celldex Therapeutics by 0.9% during the first quarter. Silverarc Capital Management LLC now owns 45,538 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 406 shares in the last quarter. First Trust Advisors LP increased its position in shares of Celldex Therapeutics by 4.4% during the third quarter. First Trust Advisors LP now owns 10,399 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 440 shares in the last quarter. Point72 Hong Kong Ltd increased its position in shares of Celldex Therapeutics by 57.9% during the first quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 511 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Celldex Therapeutics by 109.0% during the third quarter. Nisa Investment Advisors LLC now owns 1,024 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 534 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its position in shares of Celldex Therapeutics by 16.6% during the second quarter. Virtus ETF Advisers LLC now owns 4,816 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 685 shares in the last quarter.

Wall Street Analysts Forecast Growth

CLDX has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $73.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, March 1st. StockNews.com upgraded shares of Celldex Therapeutics to a “sell” rating in a report on Tuesday, December 27th.

Celldex Therapeutics Trading Up 2.0 %

Shares of Celldex Therapeutics stock opened at $44.02 on Wednesday. The company’s fifty day simple moving average is $44.53 and its 200-day simple moving average is $37.92. The stock has a market capitalization of $2.08 billion, a PE ratio of -18.42 and a beta of 2.17. Celldex Therapeutics, Inc. has a 1-year low of $19.85 and a 1-year high of $48.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 17.07 and a quick ratio of 17.07.

Celldex Therapeutics Company Profile

(Get Rating)

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.